Drugs / MMR
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03205371 | Nov 2016 → Jul 2018 | meningococcal meningitis | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MMR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03205371 ↗ |
| Modality | Vaccine | “Measles, Mumps, and Rubella Virus Vaccine Live” NCT03205371 ↗ |
| Route | Subcutaneous | “0.5 mL, Subcutaneous” NCT03205371 ↗ |